Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension

Nicholas E. King1 | Evan Brittain2

1Vanderbilt University Medical Center, Nashville, Tennessee, USA
2Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Correspondence
Evan Brittain, Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2525 West End Bldg., Room/Suite #300-A, Nashville, TN 37232, USA. Email: evan.brittain@vumc.org

Funding information
None

Abstract
Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH-LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial residual risk despite several approved therapies. Multiple lines of experimental evidence link metabolic dysfunction to the pathogenesis and outcomes in PH-LHD and PAH, and novel metabolic agents hold promise to improve outcomes in these populations. The anti-diabetic sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) agonists targeting metabolic dysfunction and improve outcomes in patients with LHD but have not been tested specifically in patients with PH. The angiotensin receptor/neprilysin inhibitors (ARNIs) produce significant improvements in cardiac hemodynamics and may improve metabolic dysfunction that could benefit the pulmonary circulation and right ventricle function. On the basis of promising preclinical work with these medications and clinical rationale, we explore the potential of SGLT2 inhibitors, GLP1 agonists, and ARNIs as therapies for both PH-LHD and PAH.

KEYWORDS
metabolic dysfunction, pulmonary arterial hypertension

INTRODUCTION

Group II pulmonary hypertension (PH) is a hemodynamic change of the pulmonary venous vasculature driven by elevated postcapillary pressure transmitted from the left heart from either heart failure with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively).1-3 Group II PH driven by left heart disease (PH-LHD) can be clinically isolated or occur in conjunction with elevated precapillary pulmonary arterial hypertension (combined pre- and postcapillary PH [CPH]), giving a spectrum of disease across the pulmonary vascular bed.1-3

PH-LHD is the most common manifestation of PH, occurring in 40%-75% of patients with HFrEF and 36%-83% with HFpEF.4-10 The prognosis following the development of PH-LHD is poor, with multiple studies showing increased mortality beyond that of left heart failure.5,7,11-14 Management for PH-LHD is limited to management of any co-occurring conditions, and to date no therapies have been shown to be effective for the prevention or progression of PH-LHD.4 Even for those patients with CPH, trials of
treatment with typical Group I pulmonary arterial hypertension (PAH) therapies such as endothelin-1 (ET-1) receptor antagonists or phosphodiesterase-5 (PDE5) inhibitors have not shown meaningfully improved outcomes.\textsuperscript{15–17} Additional studies, including ones investigating prostanoids, are ongoing; however alternative therapies need to be investigated given the lack of clear benefit in the PH-LHD and CPH populations.\textsuperscript{3}

Recently, several classes of medication have been or are anticipated to be approved to reduce clinical events in heart failure. The mechanisms of these agents suggest that they may be beneficial in patients with PH-LHD and perhaps even PAH. Accordingly, this review will investigate the work of three novel classes of medication in the setting of PH-LHD and PAH: the sodium–glucose cotransporter 2 (SGLT2) inhibitors, the glucagon-like peptide-1 (GLP1) receptor agonists, and the angiotensin receptor/neprilysin inhibitors (ARNIs) (Table 1). These agents show promise as potential therapies for both myocardial diseases that

**TABLE 1** Overview of the effects of SGLT2 inhibitor, GLP1 agonist, and ARNI therapy

| Organ               | SGLT2 inhibitors                                      | GLP1 agonists                                      | ANRI therapy                                      |
|---------------------|-------------------------------------------------------|----------------------------------------------------|---------------------------------------------------|
| Pulmonary Vasculature | • Reduce PA pressures                                    | • Reduce inflammation, fibrosis, and adverse remodeling | • Reduce PA pressures                                |
|                     | • Reduce adverse remodeling                             | • Increase nitric oxide                             | • Reduce adverse remodeling                         |
| RV myocardium       | • Reduce RV pressures                                   | • Improved RV function                             | • Reduce RV pressures                               |
|                     | • Improve metabolism                                   | • Reduce inflammation                              | • Reduce adverse remodeling                         |
|                     | • Reduce inflammation                                  | • Cardioprotective in ischemia                      | • Reduce hypertrophy                                |
|                     | • Reduce adverse remodeling                            | • Reduce adverse remodeling                         |                                                   |
| Adipose             | • Improve insulin sensitivity                           | • Improve insulin sensitivity                       | • Potentially improve insulin sensitivity           |
|                     | • Brown fat thermogenesis                              | • Weight loss                                       |                                                   |
| Renal               | • Enhance osmotic diuresis                              |                                                   | • Enhance natriuresis                               |

Abbreviations: ARNI, angiotensin receptor (blocker)/neprilysin inhibitor; GLP1, glucose-like peptide (1); PA, pulmonary artery; RV, right ventricle; SGLT2, sodium–glucose cotransporter.
leads to Group II PH and for pulmonary vascular dysfunction in patients CPH or PAH.

**Metabolic dysfunction as a driver of pulmonary vascular disease and myocardial dysfunction**

While the precise mechanisms of PH-LHD and PAH remain unclear, there is growing evidence that metabolic dysfunction is injurious to the right ventricle (RV) and pulmonary vasculature. Obesity and insulin resistance/glucose intolerance are strongly associated with increased risk of developing and can modify the severity of pulmonary vascular dysfunction manifested as Group II PH-LHD (particularly CPH) and PAH. Exposure to a high-fat diet (HFD), an inducer of metabolic dysfunction, can produce pulmonary vascular dysfunction in multiple animal models and is enhanced by alterations in apolipoprotein E, a protein involved in lipid metabolism. The HFD results in increased pulmonary vascular reactive oxygen species, inflammation, and remodeling, leading to increased pulmonary artery stiffness and pressure. Bone morphogenic protein receptor type 2 (BMPR2) mutations appear to contribute to the development of insulin resistance and weight gain in mice models of PAH. HFD exposure in BMPR2 mutant models augments the severity of PAH and is strongly correlated with fasting insulin levels rather than glucose, further suggesting metabolic dysfunction is deleterious to the pulmonary vasculature. This is significant when considering that BMPR2 mutations drive ~25% of idiopathic PAH and its expression is altered in almost all cases of connective tissue-associated PAH. Several of these HFD models have shown that the metabolic sensitizers metformin and rosiglitazone can rescue (i.e. improve insulin sensitivity, RV function, and pulmonary artery pressures in) the PAH phenotype.

Metabolic dysfunction is also toxic to the myocardium. Under normal conditions, the heart preferentially uses lipids in the form of fatty acids for energy production which is pathologically shifted to glycolysis in PAH and PH-LHD. Metabolomic profiling of PAH patients shows abnormal lipid homeostasis with increased proinflammatory lipids. The RVs of PAH patients mirror this disruption, with increased myocardial triglyceride levels and elevated markers of lipotoxic ceramides on cardiac magnetic resonance imaging. A mouse model of HFD-induced PAH showed increased myocardial lipid accumulation and hypertrophy, which correlated with impaired RV diastolic and systolic function. In well-controlled, type-2 diabetic patients without complications, myocardial triglyceride levels correlate with impaired echocardiographic strain, a marker of subclinical myocardial dysfunction. Moreover, individuals with metabolic syndrome are more likely to have RV dysfunction, with an increased incidence of RV hypertrophy, elevated pulmonary artery systolic pressures, and abnormal RV diastolic function. This unaddressed myocardial dysfunction might explain the continued deterioration of RV function in PAH despite full medical treatment with current indicated therapy such as prostacyclins, ET-1 receptor antagonists, and PDE5 inhibitors. Preclinical and clinical studies suggest that RV dysfunction may be modifiable with exposure to therapies that improve metabolic status. For example, an 8-week-long phase-2 clinical trial of metformin in patients with PAH showed significant improvement in RV fractional area change on echocardiography and decreased RV lipid content as exploratory endpoints, indicating that metabolic dysfunction is a promising therapeutic target.

Metabolic dysfunction also drives inflammation that contributes to PH. Metabolic function is closely linked to immune regulation as part of an organism’s homeostatic equilibrium. Obesity is associated with elevations in inflammatory markers such as C-reactive protein, transforming growth factor-β (TGFβ), neutrophil myeloperoxidase, and calprotectin. Adipocytes themselves produce proinflammatory signals including inflammatory fatty acids, interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNFα) which stimulate immune system activation and in turn worsen metabolic dysfunction. Animal models have shown that increased inflammatory signaling can also lead to the development of PH. Treatment of mice with exogenous IL-6 has been shown to induce PH, with animals showing increased RV pressures and RV hypertrophy. This effect was augmented by exposure to hypoxia chronic. A mouse model of IL-6 overexpression resulted in PH with the formation of T cell lesions in the pulmonary vasculature. Overexpression of Fos-related antigen 2 and resultant activation of the Fos pathway, a downstream pathway of inflammatory signaling, has been shown to result in the development of pulmonary fibrosis in mice. Lung tissue from PAH samples shows increased pulmonary vascular infiltration of chronic inflammatory cells such as T cells, B cells, and macrophages. Depletion of T cells with anti-CD4 monoclonal antibodies in an ovalbumin-induced mouse model of PH reduced pulmonary artery muscularization, further reinforcing the pathogenic nature of chronic inflammation in PH. Chronic inflammation in the pulmonary vasculature reduces nitric oxide (NO) production, increases fibrosis, and induces an endothelial to mesenchymal transition (EMT). EMT is implicated in a variety of pathologic vascular phenotypes, including
PAH where it contributes to the muscularization of the pulmonary vasculature. Chronic inflammation is also found in the RV and likely contributes to the myocardial dysfunction that exacerbates clinical deterioration in PAH. A mouse model of HFD-induced PAH showed that the anti-inflammatory fatty acid nitrooctadecenoic acid could rescue the PAH phenotype, including the metabolic dysfunction. Work is ongoing to elucidate if targeting this proinflammatory environment has a potential therapeutic target for PAH.

SGLT2 inhibitor therapy

The sodium–glucose cotransporter 2 (SGLT2) is a transport protein located in the proximal tubule of the nephron responsible for the reuptake of filtered glucose from the glomerular filtrate. The SGLT2 inhibitors block the transporter thereby lowering the reabsorption threshold of glucose, resulting in glucosuria which lowers serum glucose. Four SGLT2 inhibitors have been approved after trials showed them to be efficacious in lowering hemoglobin A1c, starting with first-in-class canagliflozin in 2013 and subsequently followed by dapagliflozin, empagliflozin, and ertugliflozin. Subsequent Food and Drug Administration (FDA)-mandated cardiovascular outcome trials of novel antidiabetic agents showed treatment with canagliflozin, dapagliflozin, and empagliflozin resulted in significant improvements in a composite outcome of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal stroke or myocardial infarction), with secondary endpoints suggesting improvement in renal function. Dapagliflozin and empagliflozin additionally showed reduced hospitalizations for heart failure. Ertugliflozin showed no significant difference in either cardiovascular or renal outcomes. This led to subsequent studies showing that canagliflozin and dapagliflozin reduce renal dysfunction, and others showing that dapagliflozin and empagliflozin improve outcomes in HFrEF. Notably, these trials did not exclude patients with PH-LHD unless they required oxygen, while they did exclude patients with PAH. Subsequent analysis of the canagliflozin cardiovascular outcomes trial (CANVAS) also showed a reduction in hospitalization and death in both the HFpEF and HFrEF subgroups.

SGLT2 inhibitors have multiple effects that may be beneficial in patients with PH-LHD. They directly address insulin resistance and improve cardiac energy utilization by reducing glycolysis and increasing fatty acid oxidation. They induce osmotic diuresis via glucosuria and have shown a primary benefit in improving outcomes in both the HFrEF and HFpEF populations. Their role in reducing the progression of chronic kidney disease (CKD) might also be therapeutically important as CKD is associated with PAH and its presence worsens outcomes. There is also growing evidence that SLGT2 inhibitors reduce inflammation and prevent cardiac remodeling, although further work is needed to determine if this is a direct effect on cardiomyocytes or secondary to improvement in the inflammatory dysmetabolic state.

Evidence is accumulating of their potential efficacy in both PAH and PH-LHD. An ex-vivo study of pulmonary and coronary arteries in a diabetic mouse model showed that SGLT inhibition, using both a nonspecific SGLT inhibitor and the SGLT2 specific inhibitor canagliflozin, resulted in direct, specific vasodilation of the pulmonary arteries. In a rat model of monocrotaline-induced PAH, empagliflozin treatment resulted in reduced mortality, hemodynamic, pulmonary vasculature and myocardial architecture alterations. A randomized, controlled, open-label trial of 78 patients with a baseline normal EF, type 2 diabetes, hypertension, and/or stable ischemic in Japan showed that treatment with dapagliflozin attenuated the development of exercise-induced PH defined as an echocardiographic RV systolic pressure (RVSP) > 50 mmHg post-exercise. The trial excluded patients with advanced heart failure (New York Heart Association class 3 or 4, or any prior heart failure hospitalization), or with a resting RVSP > 50 mmHg. EMBRACE-HF randomized 65 stable heart failure patients with preserved and reduced EF in a double-blind study of empagliflozin to study its effects on pulmonary artery (PA) pressures. All patients had implantable PA pressure monitors and the mean PA pressure of both groups on enrollment was 30 mmHg. Treatment with empagliflozin resulted in a reduction in PA diastolic pressure of 1.7 mmHg at 12 weeks. The secondary endpoints of decreased PA systolic and mean pressures were not significant, but the PA mean decrease trended towards significance (p = 0.07). The study was limited by the small sample size and significant differences in age, glomerular filtration rate, and mineralocorticoid receptor antagonist usage. Both human studies, while methodologically limited, suggest that SGLT2 inhibitors may be effective in addressing both myocardial dysfunction and pulmonary vascular disease in patients with PAH and PH-LHD. Future work is needed to explore this possibility further with adequately powered clinical trials.

GLP1 receptor agonist therapy

Glucagon-like peptide-1 (GLP1) is an incretin hormone secreted by the intestinal L cells in response to nutrients
in the gut lumen. GLP1 has pleiotropic effects with its major functions occurring at the pancreas to regulate insulin secretion, the gastrointestinal tract to coordinate digestion, adipose tissue to promote brown fat thermogenesis, and the hypothalamus to regulate satiety. GLP1 is rapidly degraded by dipeptidyl-peptidase 4 (DPP4), with a half-life of only 1–2 min. Given its beneficial effects to correct metabolic dysfunction, multiple agents were developed to target the GLP1 axis. Novel small-molecule inhibitors of DPP4 prevent degradation of endogenous GLP1. Degradation-resistant GLP1 agonists activate the GLP1 receptor. These agents are effective in lowering hemoglobin A1c and promote significant weight loss, with semaglutide generally showing superiority. GLP1 agonists have also been studied for their outcomes in cardiovascular disease, with dulaglutide, liraglutide, and semaglutide showing significant improvement in MACE outcomes primarily driven by ischemic event reductions.

The GLP1 receptor is expressed in multiple tissues, including the heart and the smooth muscle cells of the main pulmonary artery branches in primates. GLP1 agonists reduce inflammatory signaling at a cellular level, and animal studies show GLP1 agonists reduce infarct size and improve outcomes in the setting of induced acute myocardial infarction (AMI), strongly suggestive of a cardioprotective role. Following a small nonrandomized trial of 10 patients with AMI who received GLP1 agonist infusions peri-AMI and had significant improvement in post-AMI cardiac function, a larger randomized trial of GLP1 infusion in ST-elevation AMI showed a significant decrease in infarct size and increase in salvaged myocardium following coronary intervention as compared to ischemic area matched controls. A cardioprotective effect has also been shown in non-AMI settings, with GLP1 agonists improving cardiac function in the setting of dobutamine-induced cardiac stress, and in patients undergoing elective coronary intervention requiring temporary coronary artery balloon occlusion. A subsequent safety and efficacy study of higher dose GLP1 agonist in AMI showed safety but was underpowered to assay for cardioprotective effects.

Outside the ischemic setting, GLP1 agonists and DDP4 inhibitors have been evaluated for their ability to improve cardiac function. In a small nonrandomized cohort of patients with symptomatic HFrEF, a GLP1 agonist infusion resulted in improved LV function and exercise capacity, however, subsequent randomized controlled trials demonstrated no difference in outcomes with GLP1 agonists in HFrEF patients. Subsequent analysis of the EXSCEL trial showed that while exenatide had no overall benefit for patients with type 2 diabetes, in patients without heart failure it did reduce new heart failure hospitalizations and risk of death.

Diabetic patients seem to benefit most from GLP1 agonist therapy, with a large retrospective cohort showing GLP1 agonist therapy in patients with diabetes was associated with reduced incidence of new heart failure. A rat model of diabetes-induced cardiomyopathy showed the DPP4 inhibitor sitagliptin prevented myocardial remodeling and improve left ventricle (LV) function. A small randomized, double-blind trial of liraglutide in diabetic patients showed improvement in LV function on cardiac MRI. Another small randomized non-blinded trial of liraglutide versus metformin showed a significant improvement in the primary endpoint of echocardiographic strain imaging with GLP1 agonist therapy. The study additionally showed significant improvements in its secondary endpoints of reduced arterial stiffness and decreased oxidative stress as measured by serum oxidized lipids and proteins. A nondiabetic rat model of aortic-band induced HfPef showed that GLP1 agonist therapy improved LV function and survival, suggestive that GLP1 agonists can be beneficial in HfPef and act directly on cardiomyocytes to prevent adverse remodeling. Further work is needed but the animal models and clinical data suggest that GLP1 therapy could substantially reduce and possibly treat heart failure associated with metabolic dysfunction, potentially reducing the burden of PH-LHD.

The GLP1 axis is a promising target for PAH as well. In vitro studies show that GLP1 agonists reduce intracellular inflammatory signals, increase NO signaling, and prevent the EMT which is linked to abnormal lipid metabolism and a number of disease states including PAH. While the precise mechanism is yet to be fully elucidated, in hepatocytes GLP1 agonists increase lipid efflux and restore cellular viability suggesting that the restoration of normal cellular lipid metabolism is key. GLP1 agonist therapy in a rat model of bleomycin-induced idiopathic lung fibrosis (IPF) attenuated both the inflammatory and fibrotic phases of the model, improved lung architecture, and reduced RV hypertrophy. Additional studies in rat PAH models induced by bleomycin, monocrotaline, and hypoxia have shown that DPP4 agonists protect against pulmonary vascular remodeling, that the effect is abolished by GLP1 antagonist therapy, and then rescued by GLP1 agonist therapy. In these models, GLP1 activation reduced inflammatory signaling, reduced smooth muscle cell proliferation, and reversed TGFβ mediated EMT. A murine hypoxia model of PAH showed GLP1 agonist therapy improved directly measured RVSP, decreased pulmonary arteriole thickening, and augmented intrinsic NO production. An angiotensin-II induced model of
PAH in mice suggests these effects are mediated by endothelial cells, as an endothelial cell-specific GLP1 receptor knockout population showed no response to liraglutide. Additional studies are needed to determine if these effects are seen in humans, but accumulating data is encouraging that GLP1 agonists may benefit PAH.

The endogenous natriuretic peptide system: A regulator of hemodynamic and metabolic homeostasis

B-natriuretic peptide (BNP) is an endogenous natriuretic peptide-hormone released primarily from ventricular cardiomyocytes in response to stretch. Secreted Pro-BNP is cleaved to form BNP and the N-terminal fragment, NT-Pro-BNP, which is also released. BNP is cleared by binding to the natriuretic peptide clearance receptor (NPCR, also known as natriuretic peptide receptor [NPR] C) or degradation by neprilysin, an endopeptidase. Atrial natriuretic peptide (ANP) is released from the atrial cardiomyocytes and functions similarly to BNP.

The natriuretic system acts to reduce heart afterload by increasing natriuresis/diuresis, vasodilatation, and inhibition of the renin–angiotensin–aldosterone (RAA) and sympathetic axes. If not cleared by NPCR, BNP binds NPR-A and B receptors which increase intracellular cyclic guanosine monophosphate (cGMP) to trigger these effects. In the endothelium, this results in vasodilation, reduced sodium reabsorption in the nephron, RAA antagonistic intracellular signaling, and diminished sympathetic outflow from the nervous system. BNP also is a well-established biomarker of ventricular hemodynamic overload for both PAH and left heart failure.

There is growing evidence that the natriuretic system is a modulator of metabolism and that its dysfunction seen in both PAH and PH-LHD might play a causative role. Increased natriuretic peptides have been shown to promote thermogenic browning of white adipose tissue in both human and mouse adipocytes. Insulin resistance and especially obesity are associated with decreased circulating natriuretic peptides, which might represent a natriuretic peptide deficient state similar to that of insulin resistance. Adipose-specific deletion of NPCR in mice has been shown to be protective against insulin resistance, obesity, and visceral fat accumulation, potentially by decreasing natriuretic peptide clearance and shunting the natriuretic peptides to the other natriuretic peptide receptors, NPR-A and -B. Activation of NPR-A and -B receptors increases intracellular cGMP which promotes mitochondrial biogenesis, increases fat metabolism, prevents obesity, reduces insulin resistance, and attenuates inflammation. Modulation of cGMP with PDE5 inhibitors such as sildenafil and tadalafil has also been shown to result in improved metabolic function in humans, suggesting another mechanism of these agents’ action in PAH. NRPA stimulation with natriuretic peptides is protective against hypoxia-induced PAH in a mouse model, with NRPA deletion resulting in increased RV and PA pressures, and RV and pulmonary vascular remodeling.

The natriuretic system also plays a role in the regulation of the cellular architecture of the myocardium. Multiple animal studies have shown that NRPA activation and natriuretic peptides attenuate fibrosis and cardiomyocyte hypertrophy. In preclinical models, natriuretic peptide signaling counteracts profibrotic TGFβ signaling, suppresses ET-1 expression, and acts on numerous other pathways to produce these beneficial effects. A mouse model of HFD-induced HFpEF and PH-LHD found increased expression of the NPCR in the RV and that its overexpression in cardiomyocytes resulted in hypertrophy. This effect was attenuated by NPCR stimulation with a natriuretic peptide.

Angiotensin receptor/neprilysin inhibitor therapy

The natriuretic peptide system, including both BNP and ANP, therefore, has numerous effects that may benefit patients with PAH, PH-LHD, heart failure, and/or metabolic syndrome. Both BNP and NT-Pro-BNP have been well studied as prognostic biomarkers for multiple cardiovascular conditions, including PAH, and have been targeted therapeutically. Recombinant ANP was approved for decompensated heart failure in Japan in 1995. Initial trials of synthetic BNP (nesiritide) and a neprilysin inhibitor (ecadotril) showed no effect in heart failure, however, when the neprilysin inhibitor sacubitril was combined with the angiotensin receptor blocker valsartan (termed angiotensin receptor/neprilysin inhibition or ARNI), a significant improvement in cardiovascular mortality was found in patients with HFpEF. While ARNI therapy has not been shown to benefit mortality in a multinational population of patients with HFpEF, it is FDA-approved for all patients with HF as a posthoc analysis suggested a particular benefit in the postdecompensation setting.

Correcting the relative deficiency of both BNP and ANP with ARNI therapy seeks to improve cardiac hemodynamics, metabolic homeostasis, and cellular function. The available data suggests testing ANRI therapy in patients with both PAH and PH-LHD is warranted. There
is evidence that ARNI therapy directly reduces hemodynamic alterations of PH, with case series of HFrEF patients with both PH-LHD and CPH treated with ARNI therapy showing significant reductions in PA pressures, to the point of reversal of some patients’ PH. A rat model of PAH induced by PA banding showed ARNI therapy improved hemodynamics and prevented myocardial architecture disruption. A hypoxic model of PAH induced by PA banding showed ARNI therapy improved hemodynamics and prevented remodeling, and reduced PA vascular wall thickness. Combination of ANP therapy with a PDE5 inhibitor was shown in a rat model of hypoxia-induced PAH to enhance pulmonary vasculature dilation, resulting in reduced pressures and vascular remodeling beyond either agent alone. A rat model of AMI showed that ARNI therapy reduced cardiomyocyte size, hypertrophic biomarkers, and prevented interstitial fibrosis. Analysis of profibrotic serum biomarkers obtained from the participants in the PARADIGM-HF trial of ARNI therapy showed significant reductions of analytes associated with extracellular matrix fibrosis. ARNI therapy is, therefore, a potentially efficacious therapy for both PAH and PH-LHD which deserves further investigation.

CONCLUSION

Metabolic dysfunction is a likely driver of both PH-LHD and PAH due to toxic effects on both the myocardium and pulmonary vasculature. Recently developed drug classes hold promise as potential future treatments based on animal and early clinical studies. The SGLT2 inhibitors improve metabolic dysfunction, improve hemodynamic measures, and may directly prevent cardiac remodeling in animal models. Small trials in humans have shown improvements in pulmonary artery pressures with therapy. The GLP1 agonists are highly efficacious agents to treat obesity, diabetes, and metabolic dysfunction, and might prevent the onset of heart failure in diabetics. Emerging evidence suggests they might be cardioprotective by reducing cardiac remodeling in the acute ischemic and chronic heart failure setting. Animal models also show they improve RV hemodynamics and pulmonary vascular remodeling in PAH. ARNI therapy enhances natriuretic peptide signaling and has been shown to result in improved RV hemodynamics in patients with PH and heart failure. Emerging evidence implicates natriuretic peptide deficiency in metabolic dysfunction and in adverse cardiac remodeling. These findings suggest SGLT2 inhibitors, GLP1 agonists, and ARNI therapy could provide significant therapeutic benefit in patients with PH due to PAH, PH-LDH, or CPH (Table 1). Further work is needed to elucidate the mechanisms of each agent’s diverse actions and to determine if their promise translates into these highly morbid populations.

ACKNOWLEDGMENT

The authors have received no funding for this study and have no sources to declare.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

ETHICS STATEMENT

Not applicable.

AUTHOR CONTRIBUTIONS

Nicholas E. King contributed to the drafting, preparation, and editing of the manuscript. Evan Brittain contributed to the drafting and editing of the manuscript.

REFERENCES

1. Hoepera MM, Bogard HJ, Condfiffe R, Frantz R, Khanna D, Kurzyn M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl): D42–50.
2. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beagheti M, Ghofrani MA, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Mattucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoep M. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;46(4):903–75.
3. Vachiery JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, Coghlan G, Chazova I, de Marco T. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019; 53(1):1801897.
4. Rosenkranz S, Gibbs JS, Wachter R, de Marco T, Vonk-Noordegraaf A, Vachiery JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942–54.
5. Ghio S, Gavazzi A, Campana C, Insera C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37(1): 183–8.
6. Tampakakis E, Leary PJ, Selby VN, de Marco T, Cappola TP, Felker GM, Russell SD, Kasper EK, Tedford RJ. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail. 2015;3(1):9–16.
7. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure. JACC Heart Fail. 2013;1(4):290–9.

8. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(15):1119–26.

9. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010;106(2):284–6.

10. Shah AM, Shah SJ, Anand IS, Sweiitzer NK, O’Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. TOPCAT Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail. 2014;7(1):104–15.

11. Salamon JN, Kelesidis I, Msaouel P, Mazurek JA, Mannem S, Adzic A, Zolty R. Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension. J Card Fail. 2014;20(7):467–75.

12. Miller WL, Mahoney DW, Enriquez-Sarano M. Quantitative Doppler-echocardiographic imaging and clinical outcomes with left ventricular systolic dysfunction: independent effect of pulmonary hypertension. Circ Cardiovasc Imaging. 2014;7(2):330–6.

13. Hoepen MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM. Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4(6):441–9.

14. Kolte D, Lakshmanan S, Jankowich MD, Brittain EL, Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamic study. Circulation. 2013;128(5):502–10.

15. McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001;104(23):2797–802.

16. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hennes AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30(8):904–11.

17. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009;33(2):318–24.

18. Thayer TE, Levinson RT, Huang S, Assad T, Farber-Eger E, Wells QS, Mosley JD, Brittain EL. BMI is causally associated with pulmonary artery pressure but not hemodynamic evidence of pulmonary vascular remodeling. Chest. 2021;159(1):302–10.

19. Assad TR, Harken BK, Larkin EK, Glazer AM, Xu M, Wells QS, Farber-Eger EH, Sheng Q, Shyr Y, Harrell FE, Newman JH, Brittain EL. Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol. 2016;68(23):2525–36.

20. Robbins IM, Newman JH, Johnson RF, Hennes AR, Fremont RD, Piana RN, Zhao DX, Byrne DW. Association of the metabolic syndrome with pulmonary venous hypertension. Chest. 2009;136(1):31–6.

21. Brunner NW, Skhiri H, Fortenko O, Hsi A, Haddad F, Khazeni N, Zamanian RT. Impact of insulin resistance on ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant. 2014;33(7):721–6.

22. Benson L, Brittain EL, Pugh ME, Austin ED, Fox K, Wheeler L, Robbins IM, Hennes AR. Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension. Pulm Circ. 2014;4(2):311–8.

23. Frank RC, Min J, Abdelghany M, Panigagua S, Bhattacharya R, Bhambhani V, Pomerantsev E, Ho JE. Obesity is associated with pulmonary hypertension and modifies outcomes. J Am Heart Assoc. 2020;9(5):e014195.

24. Lindman BR, Davila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vlader J, Hernandez AF, Redfield MM. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541–9.

25. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help diagnose heart failure with preserved ejection fraction. Circulation. 2018;138(9):861–70.

26. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6–19.
30. Kelly NJ, Radder JE, Baust JJ, Burton CL, Lai YC, Potoka KC, Agostini BA, Wood JP, Bachman TN, Vanderpool RR, Dandachi N, Leme AS, Gregory AD, Morris A, Mora AL, Gladwin MT, Shapiro SD. Mouse genome-wide association study of preclinical group II pulmonary hypertension identifies epidermal growth factor receptor. Am J Respir Cell Mol Biol. 2017;56(4):488–96.
31. Meng Q, Lai YC, Kelly NJ, Bueno M, Baust JJ, Bachman TN, Goncharov D, Vanderpool RR, Radder JE, Hu J, Goncharova E, Morris AM, Mora AL, Shapiro SD, Gladwin MT. Development of a mouse model of metabolic syndrome, pulmonary hypertension, and heart failure with preserved ejection fraction. Am J Respir Cell Mol Biol. 2017;56(4):497–505.
32. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007;115(10):1275–84.
33. Kelley EE, Baust J, Bonacci G, Golin.
34. Brittain EL, Talati M, Fortune N, Meoli DF, West J, Hemnes AR. Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy. Pulm Circ. 2019;9(1):2045894018817741.
35. Trammell AW, Talati M, Blackwell TR, Fortune NL, Niswender KD, Fessel JP, Newman JH, West JD, Hemnes AR. Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension. Pulm Circ. 2017;7(3):624–34.
36. West J, Niswender KD, Johnson JA, Pugh ME, Gleave L, Fessel JP, Hemnes AR. A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J. 2013;41(4):861–71.
37. Hemnes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, Maynard KB, Gleave L, Talati M, Abi T, Disalvo T, West J. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2014;189(3):325–34.
38. Talati MH, Brittain EL, Fessel JP, Penner N, Atkinson J, Funke M, Grueter C, Jerome WG, Freeman N, Newman JH, West J, Hemnes AR. Mechanisms of lipid accumulation in the bone morphogenetic protein receptor type 2 mutant right ventricle. Am J Respir Crit Care Med. 2016;194(6):719–28.
39. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105(14):1672–8.
40. Dewachter L, Adnot S, Guignabert C, Tu L, Marcos E, Fadel E, Humbert M, Dartevelle P, Simonneau G, Naeije R, Eddahibi S. Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. Eur Respir J. 2009;34(5):1100–10.
41. Andruska A, Spiekerkoetter E. Consequences of BMPR2 deficiency in the pulmonary vasculature and beyond: contributions to pulmonary arterial hypertension. Int J Mol Sci. 2018;19(9):2499.
42. Tran DH, Wang ZV. Glucose metabolism in cardiac hypertrophy and heart failure. J Am Heart Assoc. 2019;8(12):e012673.
43. Koop AC, Bossers GPL, Ploegstra MJ, Hagdorn Q, Berger R, Silljé H, Bartelds B. Metabolic remodeling in the pressure-loaded right ventricle: shifts in glucose and fatty acid metabolism—a systematic review and meta-analysis. J Am Heart Assoc. 2019;8(21):e012086.
44. Hemmes AR, Luther JM, Rhodes CJ, Burgess JP, Carlson J, Fan R, Fessel JP, Fortune N, Gerszten RE, Halliday SJ, Hekmat R, Howard L, Newman JH, Niswender KD, Pugh ME, Robbins IM, Sheng Q, Shibao CA, Shyr Y, Sumner S, Talati M, Wharton J, Wilkins MR, Ye F, Yu C, West J, Brittain EL. Human PAH is characterized by a pattern of lipid-related insulin resistance. JCI Insight. 2019;4(1):123611.
45. Brittain EL, Talati M, Fessel JP, Zhu H, Penner N, Calcutt MW, West JD, Funke M, Lewis GD, Gerszten RE, Hamid R, Pugh ME, Austin ED, Newman JH, Hemnes AR. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. Circulation. 2016;133(20):1936–44.
46. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, Hooi Ewe S, Siebelink HM, Smit JW, Diamant M, Romijn JA, de Roos A, Leung DY, Lamb HJ, Bax JJ. Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation. 2010;122(24):2538–44.
47. Lopez-Candales A, Hernandez-Suarez DF. Strain imaging echocardiography: what imaging cardiologists should know. Curr Cardiol Rev. 2017;13(2):118–29.
48. Gopal DM, Santhanakrishnan R, Wang YC, Ayalon N, Donohue C, Rahban Y, Perez AJ, Downing J, Liang CS, Gokce N, Colucci WS, Ho JE. Impaired right ventricular hemodynamics indicate preclinical pulmonary hypertension in patients with metabolic syndrome. J Am Heart Assoc. 2015;4(3):e001597.
49. Whitaker ME, Nair V, Sinari S, Dherange PA, Natarajan B, Trutter L, Brittain EL, Hemnes AR, Austin ED, Patel K, Black SM, Garcia J, Yuan Md PhD JX, Vanderpool RR, Rischard F, Makino A, Bedrick EJ, Desai AA. Diabetes mellitus associates with increased right ventricular afterload and remodeling in pulmonary arterial hypertension. Am J Med. 2018;131(6):702.
50. van de Veerendonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24):2511–9.
51. Brittain EL, Niswender K, Agrawal V, Chen X, Fan R, Pugh ME, Rice TW, Robbins IM, Song H, Thompson C, Ye F, Yu C, Zhu H, West J, Newman JH, Hemnes AR. Mechanistic phase II clinical trial of metformin in pulmonary arterial hypertension. J Am Heart Assoc. 2020;9(22):e018349.
52. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–85.

53. Shemesh T, Rowley KG, Jenkins A, Brimblecombe J, Best JD, O’Dea K. Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeastern Arnhem Land of Australia. Int J Obes (Lond). 2007;31(1):103–8.

54. Nijhuis J, Rensen SS, Slats Y, van Dielen FM, Buurman WA, Greve JW. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring). 2009;17(11):2014–8.

55. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Sciarretta S, Ferrucci A, Ciavarella G, Depaolis P, Hotamisligil GS. Inflammation, metaflammation and cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens. 2006;20(7):784–91.

56. Herder C, Zierer A, Koenig W, Roden M, Meisinger C, Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Golembeski SM, West J, Tada Y, Fagan KA. Interleukin-128(6):572S.

57. Golembeski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest. 2005;128(6):572S–3S.

58. Steiner MK, Syrka OA, Koliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104(2):236–44.

59. Efferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Konnenovic V, Idarraga MH, Kenner L, Wagner EF. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci. 2008;105(30):10525–30.

60. Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheer A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(9):897–908.

61. Marsh LM, Jandl K, Grünig G, Foris V, Bashir M, Ghanim B, Klepetko W, Olschewski H, Olschewski A, Kwapiszewksa G. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2018;51:1.

62. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Luiten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, Grunig E, Grunig G. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med. 2008;205(2):361–72.

63. Huertas A, Tu L, Humbert M, Guignabert C. Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. Cardiovasc Res. 2020;116(5):885–93.

64. Gorelova A, Berman M, Al Ghouleh I. Endothelial-to-mesenchymal transition in pulmonary arterial hypertension. Antioxid Redox Signal. 2020;34(12):891–914.

65. Helmke A, Casper J, Nordlohne J, David S, Haller H, Zeisberg EM, von Vietinghoff S. Endothelial-to-mesenchymal transition shapes the atherosclerotic plaque and modulates macrophage function. FASEB J. 2019;33(2):2278–89.

66. Ranchoux B, Antigny M, Laufert A, Péchoux C, Bogaard HJ, Dorfmüller P, Remy S, Lecerf S, Planté S, Chat S, Fadel E, Houssaini A, Anegon I, Adnot S, Simonneau G, Humbert M, Cohen-Kaminsky S, Perros F. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2015;131(11):1006–18.

67. Sun X-Q, Abbate A, Bogaard H-J. Role of cardiac inflammation in right ventricular failure. Cardiovasc Res. 2017;113(12):1441–52.

68. Overbeek MJ, Mouchaers KTB, Niessen HM, Hadi AM, Kupreishvili K, Boonstra A, Voskyel AE, Belien JAM, Smit EF, Dijkmans BC, Vonk-Noordegraaf A, Grünberg K. Characteristics of interstitial fibrosis and inflammatory cell infiltration in right ventricles of systemic sclerosis-associated pulmonary arterial hypertension. Int J Rheumatol. 2010;2010:604515.

69. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein J, Cornel JH, Pias P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi P, Troquay R, Libby P, Glynn RJ, CANTOS Trial Group. Anti-inflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.

70. Goldenberg NM, Rabinovitch M, Steinberg BE. Inflammatory basis of pulmonary arterial hypertension: implications for perioperative and critical care medicine. Anesthesiology. 2019;131(4):898–907.

71. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761–80.
metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508–15.
87. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–50.

90. Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D, Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–82.
99. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Woerle HJ, Broedl UC, EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–23.

92. Packer M, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masukieziewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney D, McGuire DK, VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.
93. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masukieziewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney D, McGuire DK, VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.

95. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Trans Sci. 2020;5(6):632–44.

96. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinari J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schraut S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61.

97. O’Leary JM, Assad TR, Xu M, Birdwell KA, Sabo‐Eger E, Wells QS, Hemnes AR, Brittain EL. Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes. Pulm Circ. 2017;7(3):674–83.

98. Nickel NP, O'Leary JM, Brittain EL, Fessel JP, Zamanian RT, Iannantuoni F, M. de Marañon A, Diaz‐Valenzuela E, Ayon R, Guo R, Youssef KD, Pan M, Eger E, Ayon R, Guo R, Youssef KD, Pan M, Chen AS, Lin CY, Huang CY, Wu CL, Pan H, Wang SL, Wang AH, Lin JS, Chang BC, Wang YH, Wang AT, Lin CY, Huang CY, Wu CL, Pan H, Wang SL, Wang AH, Lin JS, Chang BC, Wang YH, Watanabe N, Hamazaki Y, Geshi E, Murakami M, Aihara K, Kaneko K, Yamada H, Kobayashi Y, Shinko T. Dapagliflozin influences ventricular hemodynamics and exercise‐induced pulmonary hypertension in type 2 diabetes patients—a randomized controlled trial. Circ J. 2020;84(10):1807–17.

99. Juniper ER, Brandt SD, Wilson J, James CD, Chalmers J, Gray JP, Mason P, Williams B, Brazil J, Sibbald B, Paterson DL. Semaglutide for type 2 diabetes mellitus: a systematic review and mixed treatment comparison. Diabetes Ther. 2019;5(1):1–41.

100. van der Meer FJ, Meersma GJ, Boerma J, Anker SD, Anker SD. The sodium–glucose co‐transporter 2 inhibitor empagliflozin attenuates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med. 2019;8:11.

101. Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzl A, Mayer G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62(7):1154

102. Leng W, Wu M, Pan H, Lei X, Chen L, Wu Q, Ouyang X, Liang Z. The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS‐NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Ann Transl Med. 2019;7(18):429.

103. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310.

104. Kang S, Verma S, Hassanabad AF, Teng G, Belde DD, Dundas JA, Guzzardi DG, Szystonuik DA, Mattar SS, Park D, Turnbull JD, Duff JJ, Tipples LA, Cunnington RH, Dyck J, Fedak P. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA‐REG OUTCOME results. Can J Cardiol. 2020;36(4):543–53.

105. Han Y, Cho Y‐E, Ayon R, Guo R, Guo R, Youssef KD, Pan M, Dai A, Yuan JXJ, Makino A. SGLT inhibitors attenuate NO‐dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol‐Lung Cell Mol Physiol. 2015;309(9):L1027–L36.

106. Chowdhury B, Luu AZ, Luu VZ, Kabir MG, Pan Y, Teoh H, Quan A, Sabongui S, Al‐Omran M, Bhatt DL, Mazer CD, Connelly KA, Verma S, Hess DA. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem Biophys Res Commun. 2020;524(1):50–6.

107. Kayano H, Koba S, Hirano T, Matsui T, Fukuo H, Tsujiita H, Tsukamoto S, Hayashi T, Toshida T, Watanabe N, Hamazaki Y, Geshi E, Murakami M, Aihara K, Kaneko K, Yamada H, Kobayashi Y, Shinko T. Dapagliflozin influences ventricular hemodynamics and exercise‐induced pulmonary hypertension in type 2 diabetes patients—a randomized controlled trial. Circ J. 2020;84(10):1807–17.

108. Nassis ME, Qintar M, Windsor SL, Jermyn R, Shavell DM, Tang F, Lamba S, Bhatt K, Brush J, Civitello A, Gordon R, Jonsson O, Lampert B, Pelzel J, Kosiborod MN. Empagliflozin effects on pulmonary artery pressure in patients with heart failure. Circulation. 2021;143(17):1673–86.

109. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon‐like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403.

110. Beiroa D, Imbemnon M, Gallego R, Senra A, Herranz D, Villarroya F, Serrano M, Ferno J, Salvador J, Escalada J, Dieguez C, Lopez M, Frühbeck G, Nogueiras R. GLP‐1 agonism stimulates brown adipose tissue thermogenesis and burning through hypothalamic AMPK. Diabetes. 2014;63(10):3346–58.

111. Deacon CF. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):34–46.

112. Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014;5(1):1–41.

113. Hütte ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed‐treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–36.

114. Andreidis P, Karagiannis T, Malandrinos K, Averinos I, Liakos A, Manolopoulos A, Bekiari E, Matthews DR, Tsapas A. Semaglutide for type 2 diabetes mellitus: a systematic review and meta‐analysis. Diabetes Obes Metab. 2018;20(9):2255–63.

115. Pl-Sunyer X, Astrapu A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.

116. Davies M, Førch L, Jeppesen OK, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, STEP Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84.

117. Capehorn MS, Catarić AM, Furbeg J, Janez A, Price HC, Tadayon S, Vergès B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as...
add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9.

118. Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A, SUSTAIN 7 Investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–86.

119. Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ, PIONEER 4 Investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIO-NEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.

120. Marso SP, Bain SC, Consoli A, Eliaschwitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

121. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeier JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Hall S, Dive C, Roa-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Henefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WHH, Temelkova-Kurttschiev T, Abella M, Alebuena A, Silljé HH, Meissner M, van Gilst WH, de Boer RA, Despres JP, Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

122. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeier JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Hall S, Dive C, Roa-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Henefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WHH, Temelkova-Kurttschiev T, Abella M, Alebuena A, Silljé HH, Meissner M, van Gilst WH, de Boer RA, Despres JP, Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
135. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408–13.

136. Bernink FJ, Timmers L, Diamant M, Scholte M, Beek AM, Kamp O, Marques KM, Denham RN, Chen WJ, Doevendans PA, van Rossum AC, van Royen N, Horrevoets AJ, Appelman Y. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study. Int J Cardiol. 2013;167(1):289–90.

137. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Velez M, Peterson EL, Wells K, Swadia T, Sabbah HN, Bizino MB, Jazet IM, Westenberg JJM, van Eyk HJ, Paiman E, Smit J, Lamb HJ. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18(1):55.

138. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flynnbjergh A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69–77.

139. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–9.

140. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Pouliner T, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

141. Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Öhman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ. Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial. Circulation. 2019;140(20):1613–22.

142. Velez M, Peterson EL, Wells K, Swadia T, Sabbah HN, Williams LK, Lanfear DE. Association of antiobesity medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail. 2015;21(1):2–8.

143. Bostick B, Habibi J, Ma L, Aroor A, Rehmer N, Hayden MR, Sowers JR. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism. 2014;63(8):1000–11.

144. Bizino MB, Jazet IM, Westenberg JJM, van Eyk HJ, Paiman E, Smit J, Lamb HJ. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18(1):55.

145. Lambidiari V, Pavlidis G, Kousathanas F, Varoudi M, Vlastos D, Maratou E, Georgiou D, Andreadou I, Parissis J, Triantafyllidi H, Lekakis J, Ilidromititis E, Dimitriadis G, Ikonomidou I. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide at arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):8.

146. Nguyen TD, Shingu Y, Amorim PA, Schenkl C, Schwarzer M, Doenst T. GLP-1 improves diastolic function and survival in heart failure with preserved ejection fraction. J Cardiovasc Transl Res. 2018;11(3):259–67.

147. Wang J, Yu M, Xu J, Cheng Y, Li X, Wei G, Wang H, Kong H, Xie W. Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension. J Biomed Sci. 2019;26(1):6.

148. Xiong J, Kawagishi H, Yan Y, Liu J, Wells QS, Edmunds LR, Fergusson MM, Yu ZX, Rovira II, Brittain EL, Wolfgang MJ, Jurczak MJ, Fessel JP, Finkel T. A metabolic basis for endothelial-to-mesenchymal transition. Mol Cell. 2018;69(4):689–98.

149. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE−/− mouse model. Diab Vasc Dis Res. 2011;8(2):117–24.

150. Yao Y, Li Q, Wang W, Zhang J, Gao P, Xu Y. Glucagon-like peptide-1 modulates cholesterol homeostasis by suppressing the miR-19b-induced downregulation of ABCA1. Cell Physiol Biochem. 2018;50(2):679–93.

151. Fandiño J, Toba L, González-Matías LC, Díz-Chaves Y, Mallo F. GLP-1 receptor agonist ameliorates experimental lung fibrosis. Sci Rep. 2020;10(1):18091.

152. Xu J, Wang J, He M, Han H, Xie W, Wang H, Kong H. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension. Lab Invest. 2018;98(10):1333–46.

153. Honda J, Kimura T, Sakai S, Maruyama H, Tajiri K, Murakoshi N, Homma S, Miyachuchi T, Aonuma K. The glucagon-like peptide-1 receptor agonist liraglutide improves hypoxia-induced pulmonary hypertension in mice partly via normalization of reduced ET(B) receptor expression. Physiol Res. 2018;67(Suppl 1):S175–S84.

154. Steven S, Helmastraeter J, Filippou K, Pawelke F, Katie F, Vujacic-Mirski K, Kalinovic SS, Kroeller-Schoen S, Oelze M, Munzel T, Daiber A. P4476Cardiovascular benefits of GLP-1 (liraglutide) treatment in experimental arterial hypertension are mediated by the endothelial GLP-1 receptor. Eur. Heart J. 2019;40(Supplement 1):2699. https://doi.org/10.1093/eurheartj/ehz745.0871

155. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339(5):321–8.

156. Kerkelä R, Ulvila J, Magga J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc. 2015;4(10):e002423.

157. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart (Br Card Soc). 2006;92(6):843–9.
158. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27(1):47–72.

159. Winquist RJ, Faison EP, Waldman SA, Schwartz K, Murad F, Rapoport RM. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA. 1984;81(23):7661–4.

160. Sonnenberg H, Honrath U, Chong CK, Wilson DR. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol. 1986;250(6 Pt 2):F963–6.

161. Johnston CI, Hodsman PG, Kohzuki M, Casley DJ, Fabris B, Phillips PA. Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists. Am J Med. 1989;87(6b):24s–8s.

162. Imaiizumi T, Takeda A, Higashi H, Nakamura M. alpha-ANP alters reflex control of lumbar and renal sympathetic nerve activity and heart rate. Am J Physiol. 1987;253(5 Pt 2):H1136–40.

163. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Draznin MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803.

164. Fijalkowska A, Torbicki A. Role of cardiac biomarkers in assessment of RV function and prognosis in chronic pulmonary hypertension. Eur Heart J. 2007;28(Suppl H):H41–H7.

165. Bordicchia M, Liu D, Amri E-Z, Ailhaud G, Dessì-Koivunen K, Z, Ailhaud G, Dessì. Prostatin induces apoptosis in human prostate cancer cells: role of phosphatidylinositol 3-kinase/Akt and caspase 3. FASEB J. 2003;17(13):1531–2.

166. Wu W, Shi F, Liu D, Ceddia RP, Gaffin R, Wei W, Fang H, Lewandowski ED, Collins S. Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. Sci Signal. 2017;10(489):eaam6870.

167. Miyashita K, Itoh H, Tsuchimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T, Nakao K. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes. 2009;58(12):2880–92.

168. Pandey KN. Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes phosphoinositide hydrolysis, Ca2+ release, and activation of protein kinase C. Front Mol Neurosci. 2014;7(75):75.

169. Peifer A, Kilić A, Hoffmann LS. Regulation of metabolism by cGMP. Pharmacol Ther. 2013;140(1):81–91.

170. Hill KD, Eckhauser AW, Marney A, Brown NJ. Phosphodiesterase 5 inhibition improves cell function in metabolic syndrome. Diabetes Care. 2009;32:857–9.

171. Ramirez CE, Nian H, Yu C, Gamboa JL, Luther JM, Brown NJ, Shibao CA. Treatment with sildenafil improves insulin sensitivity in prediabetes: a randomized, controlled trial. J Clin Endocrinol Metab. 2015;100(12):4533–40.

172. Zhao L, Long L, Morrell NW, Wilkins MR. NPR-A-deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation. 1999;99(5):605–7.

173. Kapoun AM, Liang F, O'young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Prower AA. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts. Circ Res. 2004;94(4):453–61.

174. Glenn DJ, Rahmutula D, Nishimoto M, Liang F, Gardner DG. Atrial natriuretic peptide suppresses endothelin gene expression and proliferation in cardiac fibroblasts through a GATA4-dependent mechanism. Cardiovasc Res. 2009;84(2):209–17.

175. Agrawal V, Fortune N, Yu S, Fuente J, Shi F, Nichols D, Gleaves L, Poovey E, Wang TJ, Brittain EL, Collins S, West JD, Hennes AR. Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. Pulm Circ. 2019;9(4):2045894019878599.

176. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352(7):666–75.

177. Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, Hill SA, Balion C, Booth RA, Brown JA, Bustamam A, Sohel N, Raina P. BNP and NT-proBNP as prognostic markers in persons with acute compensated heart failure: a systematic review. Eur J Heart Fail. 2014;16(4):453–70.

178. Doust JA, Pietrzak E, Dobson A, Glassiou F. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330(7492):625.

179. Berger R, Huelmsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105(20):2392–7.

180. Koglin J, Pehlivanli S, Schwalbalm MA, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38(7):1934–41.

181. Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E, Chaouat A, Chabanon C, Bourdin A, Parent F, Montani D, Simonneau G, Humbert M, Sitbon O. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889.
184. Sitbon O, Chinnick RN, Benza RL, Di Scala L, Gaine S, Ghofrani HA, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Tapson VF, Galié N, Hoepf MM. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. J Heart Lung Transplant. 2020;39(4):300–9.

185. Anderson JJ, Lau EM, Lavender M, Benza R, Celermajer DS, Collins N, Corrigan C, Dwyer N, Feenstra J, Horrow M, Kermeen F, Kotlyar E, McWilliams T, Rhodes B, Steele P, Thakkar V, Williams T, Whitford H, Whyte K, Weintraub R, Wrobel JP, Keogh A, Strange G. Retrospective validation of the REVEAL 2.0 risk score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort. Chest. 2020;157(1):162–72.

186. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J. 2005;69(3):283–90.

187. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet (London, Eng). 1998;351:1657–8.

188. Dandamudi S, Chen HH. The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompenated heart failure. Expert Rev Cardiovasc Ther. 2012;10(5):557–63.

189. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–48.

190. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.

191. Solomon SD, McMurray J, Anand IS, Ge J, Lam C, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Hjund PS, Boyts SA, Comin-Colet J, Cleland J, Dünge H, Conalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Sen M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.

192. Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, Janssens S, Milicic D, Arango JL, Packer M, Shi VC, Lefkowitz MP, McMurray J, Solomon SD. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol. 2020;75(3):245–54.

193. de Simone V, Guarise P, Zanotto G, Morando G. Reduction in pulmonary artery pressures with use of sacubitril/valsartan. J Cardiol Cases. 2019;20:187–90.

194. Zern EK, Cheng S, Wolfson AM, Hamilton MA, Zile MR, Solomon SD, Kittleston MM. Angiotensin receptor-neprilysin inhibitor therapy reverses pulmonary hypertension in end-stage heart failure patients awaiting transplantation. Circ Heart Fail. 2020;13(2):e006696.

195. Kia DS, Benza E, Bachman TN, Tushak C, Kim K, Simon MA. Angiotensin receptor-neprilysin inhibition attenuates right ventricular remodeling in pulmonary hypertension. J Am Heart Assoc. 2020;9(13):e015708.

196. Clements RT, Vang A, Fernandez-Nicolás A, Kue NR, Mancini TJ, Morrison AR, Mallem K, McCullough DJ, Choudhary G. Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril/valsartan. Circ Heart Fail. 2019;12(11):e005819.

197. Ballan RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, Wilkins MR, MacAllister RJ, Hobs AJ. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(8):861–9.

198. Pflau D, Thorn SL, Zhang J, Mikush N, Renaud JM, Klein R, deKemp RA, Wu X, Hu X, Sinunas AJ, Young LH, Tirzii D. Angiotensin receptor neprilysin inhibitor attenuates myocardial remodeling and improves infarct perfusion in experimental heart failure. Sci Rep. 2019;9(1):5791.

199. Zile MR, O’Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, Packer M, McMurray J, Shi V, Lefkowitz M, Rouleau J. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019;73(7):795–806.

How to cite this article: King NE, Brittain E. Emerging therapies: the potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulm Circ. 2022;12: e12028. https://doi.org/10.1002/pul2.12028